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Abstract
Background
Many genes are candidates for involvement in epileptic encephalopathy (EE)
because one or a few possibly pathogenic variants have been found in
patients, but insufficient genetic or functional evidence exists for a definite
annotation.
Methods
To increase the number of validated EE genes, we sequenced 26 known and
351 candidate genes for EE in 360 patients. Variants in 25 genes known to be
involved in EE or related phenotypes were followed up in 41 patients. We pri-
oritized the candidate genes, and followed up 31 variants in this prioritized
subset of candidate genes.
Results
Twenty-nine genotypes in known genes for EE (19) or related diseases (10),
dominant as well as recessive or X-linked, were classified as likely pathogenic
variants. Among those, likely pathogenic de novo variants were found in EE
genes that act dominantly, including the recently identified genes EEF1A2,
KCNB1 and the X-linked gene IQSEC2. A de novo frameshift variant in candi-
date gene HNRNPU was the only de novo variant found among the followed-
up candidate genes, and the patient’s phenotype was similar to a few recent
publications.
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aEuroEPINOMICS RES – working group
collaborators are listed in Appendix 1.
Conclusion
Mutations in genes described in OMIM as, for example, intellectual disability
gene can lead to phenotypes that get classified as EE in the clinic. We con-
firmed existing literature reports that de novo loss-of-function HNRNPUmuta-
tions lead to severe developmental delay and febrile seizures in the first year of
life.
Introduction
According to the ILAE definition epileptic encephalopathy
(EE) is a condition in which “the epileptiform electroen-
cephalographic (EEG) abnormalities themselves are
believed to contribute to a progressive disturbance in
cerebral function” (Engel and International League
Against 2001). It is a highly heterogeneous disorder, with
variation in the age at onset, the type and distribution of
seizures, developmental outcome,EEG patterns, the
response to medication, and a wide range of comorbidi-
ties. Genetically, it is just as heterogeneous, and OMIM
currently lists 32 genes recognized for early infantile EE
(EIEE), with different inheritance modes (data accessed
August 2015). Apart from this list, patients who are diag-
nosed with EE regularly turn out to have a pathogenic
variant in a gene that is annotated for intellectual disabil-
ity with seizures (Hirose and Mitsudome 2003). With the
current list of genes associated with EE, a genetic diagno-
sis in the clinic can be made in ~10-15% of referred
patients (pers. comm. Marjan van Kempen). Since in the
majority of these patients a variant of large effect is
expected, this means many genes that may cause EE when
mutated probably remain to be discovered.
Several recent efforts have been undertaken to identify
additional EE genes. For example, the Epi4K effort
sequenced 264 parent-offspring trios of patients with
infantile spasms or Lennox–Gastaut syndrome using
whole exome sequencing (WES) (Epi4K-Consortium et al.
2013; Consortium et al. 2014). They identified on average
1.25 de novo variants per person in those patients. Yet,
only nine novel genes showed a significant excess of de
novo variants and could be classified as EE genes, explain-
ing the condition in 29 patients. For the genes with one
or two de novo hits in the whole cohort, the status
remained unclear. Other efforts using whole exome
sequencing or targeted sequencing (Carvill et al. 2013;
Kodera et al. 2013; Ohba et al. 2013; Veeramah et al.
2013; Consortium et al. 2014) have identified a number
of genes enriched for variants in patients with EE. Yet,
also in these efforts, de novo variants in many candidate
genes were not observed to be significantly overrepre-
sented in patients, possibly due to small numbers. The
number of de novo hits required to confidently link a
gene to a specific disease depends on the number of
patients involved in studies and gene size, as well as on
supportive evidence from clinical (similarity among
patients with variants in the same gene) and/or functional
studies. Recessive diseases are often, though not always,
caused by inherited variants, and even more stringent cri-
teria for pathogenicity should be applied. In many recent
publications homozygous or compound heterozygous hits
have been found in two or three sibs only (Simpson et al.
2004; Banne et al. 2013; Basel-Vanagaite et al. 2013;
Paciorkowski et al. 2014), which is not statistically con-
vincing. Here too, additional support is required.
In our current study, we aimed to increase the number
of known genes for EE by confirming the involvement of
candidate genes from previous studies using targeted rese-
quencing in 359 unrelated patients. As the majority of
previous studies focused on genes that cause EE in a
dominant fashion, we included genes that influence EE in
an X-linked or recessive fashion with priority. We also
preferentially included probands from consanguineous
and multiplex families. We included known EE genes in
the design because patients were not previously tested
exhaustively for all known genes. Thus, we could sort
results into results for patients with known causes and
those for whom a novel cause would be more likely. We
present our results for the cohort of 359 independent
patients.
Methods
Samples
Patients included in this study had an onset of seizures
and concomitant intellectual disability (ID) before the age
of five years, and no pathogenic variants had been identi-
fied in previous diagnostic testing. Samples were collected
by multiple centers, and previous genetic testing had been
carried out following local guidelines. The majority of
patients were European, but at least 68 patients were
Arab, Turkish, or North-African, according to their par-
ents’ specification. The parents of 209 patients collected
in the Netherlands, Belgium, France, Germany, Denmark,
and Bulgaria were not specifically asked about their
ethnicity. Of these, at least 17 were likely non-European
based on family name; the others were likely in majority
of European descent.
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In total, 359 samples were included including two sibs.
Sixty-five probands had affected family members, mainly
sibs, who were not included in the study. In most of these
patients, there was no known relationship between the
parents. Forty-one patients were sporadic cases, but with
related parents. The patients with affected sibs would
likely have a recessive inheritance, since parents were not
suffering from EE. However, the possibility of parental
mosaicism cannot be neglected. The sporadic patients
with related parents are likely enriched for recessive
inheritance as well. We had 155 females and 204 males.
In this article, we will refer to our dataset as “TEGA”
(Targeted Epilepsy Genes Array).
Ethical compliance
Ethical approval and consent were obtained at the local
institutions. Collection of patients was reviewed and
approved by local ethics committees.
Sequencing and mapping
Genes were collected up to a footprint of ~ 1.2 Mb. We
collected genes from the following studies: (Simpson et al.
2004; Striano et al. 2007; Backx et al. 2009; Janer et al.
2012; Banne et al. 2013; Basel-Vanagaite et al. 2013; Car-
vill et al. 2013; Fr€uhmesser et al. 2013; Kodera et al.
2013; Ohba et al. 2013; Veeramah et al. 2013; Consortium
et al. 2014; Paciorkowski et al. 2014),and from our own
earlier experiments. More information on many of the
genes may also be found on: http://122.228.158.106/Epi-
lepsyGene/index.php.We included known genes for EIEE
from OMIM as well. This resulted in 273 genes that are
described as influencing EE phenotypes in an autosomal
dominant fashion, 68 that act as autosomal recessive, 2
not clear, 26 X-linked, and 1 mitochondrial genes. A list
of genes and some characteristics, for example, expected
mode of inheritance and reason for inclusion can be
found in Table S1. In August 2015, twenty-seven genes in
our design were listed in OMIM as genes causing EE or
very similar phenotypes (128,435 bp); 25 of our genes
were annotated with phenotypes that included mental
retardation or metabolic disorders, but had been found
mutated in EE patients before (143,815 bp). The remain-
ing 290 genes were not annotated for a suspect phenotype
(889,391 bp), though a few are associated with GEFS+ or
other milder epilepsy phenotypes (Table S1).
Probes for enrichment were designed and ordered from
Agilent Technologies (Santa Clara, CA, USA) as Sure
Select enrichment kit. Experimental workflow followed
the standard protocols. Sequencing was done on a
SOLiD5500XL. Alignment, variant calling, and annotation
were done using an in-house pipeline, which used a
BWA-aligner and a GATK-based variant caller versus
Human reference GhCr37/hg19 (McKenna et al. 2010).
Aligned data were processed following the Genome Anal-
ysis Toolkit (GATK) best practices v2. Reads were rea-
ligned around indels, using GATK IndelRealigner, and
base quality scores were recalibrated, using GATK
BaseRecalibrator. Annotation was based on Ensembl
GRCh37.p13 and dbSNP 144.
Quality control and filtering
Variants were included if they had at least 10x coverage,
an alternative variant call of at least 20%, and were anno-
tated as affecting the protein. Variants that were seen in
more than eight additional samples per plate at low per-
centages of variant alleles (< threshold of 20%) were
excluded, since these probably constitute noise. Positions
that showed a third allele at >4% of reads averaged over
all samples per plate were also excluded, as probable arti-
facts. Positions that had failed in more than 10% of the
samples were only included after visual inspection.
For dominant genes, we included only variants not
listed in dbSNP v144, on the ESP server (http://
evs.gs.washington.edu/EVS/ May 2015) or the ExAC data-
base (http://exac.broadinstitute.org, June 2015). These
variants we annotated as “novel.” We added variants that
were annotated as “of clinical significance” in dbSNP, if
this annotation referred to epilepsy or epilepsy-related
disorders. For autosomal and X-linked recessive genes as
well as for the female-specific X-lined gene PCHD19
(MIM 300460), we added variants that were annotated as
having a population frequency of at most 0.001. We
checked that no homozygotes or X-linked hemizygotes of
this variant were observed in the databases ESPor ExAC
(except for PCDH19). Variants that were seen in more
than two patients in our panel of 359 independent sam-
ples were excluded.
Follow-up
Variants were annotated with their CADD-score (Kircher
et al. 2014), SIFT (Kumar et al. 2009; Hu and Ng 2012),
Polyphen-2 (Adzhubei et al. 2013), Grantham (Grantham
1974) and Gerp-score (Cooper et al. 2005) (when avail-
able), and the T/D annotation of MetaLR (Dong et al.
2015). Variants in known genes for EE were Sanger-
sequenced in the patient as well as in the parents if DNA
was available (N = 41). Clinical experts assessed whether
causality was likely based on previously published pheno-
types for these genes, and the clinician’s experience.
Patients with a pathogenic variant in a known EE gene
were flagged. Variants in a subset of candidate genes were
followed-up (N = 31), as explained below.
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Prioritization
To prioritize genes for follow-up, we wanted to identify
genes with an excess of novel variants in our patients. The
frequency of unique variants in our patients was compared
to the frequency in the ExAC database as follows.
For all genes on our design, the coding variants were
downloaded from the ExAC-database, along with the
number of alleles that were seen in the database at that
position. We combined these data with our results and
selected those variants that were seen only once in this
combined dataset. The frequency of unique variants was
compared between the datasets with a Fisher exact test.
We ranked the genes with excess variation in our dataset
according to the P-value.
We selected a subset of candidate genes for follow-up
based on ranking in our excess-list and preliminary data
of parallel studies of consortium members. For this subset
of variants, we used Sanger sequencing in DNA samples
from the proband and the parents – if available – to
assess whether the inheritance pattern confirmed our
expectation, i.e. de novo for heterozygous variants in
dominant-acting genes; homozygous, compound
heterozygous, or de novo for double hits in autosomal
recessive-acting genes; de novo or inheritance from
mother in X-linked recessive-acting genes; de novo or
inheritance from healthy father or affected mother for
PCDH19.
To get more insight, we compared the unique variants
listed in ExAC with the unique variants found in our
patients on the CADD score for deleteriousness. The
CADD-score incorporates a large number of other scores,
and was designed to identify deleterious variants rather
than, for example, variants with any effect on the protein
functioning. We also compared CADD-scores of de novo
variants in dominant-acting EE-genes with CADD-scores
of inherited variants.
Statistics
To test whether known EE genes were overrepresented
among the genes with excess novel variants we used a
chi-square test for independence. This test was also used
to test whether recessive disorders were overrepresented
among children from related parents, and to test whether
LoF variants were overrepresented in genes that were clas-
sified as intolerant to LoF.
To compare CADD-scores between groups of genes or
groups of variants, we performed ANOVA tests on the
raw CADD-scores, rather than the phred-scores, as their
distribution was closer to normal.
To compare the number of unique variants per gene in
our patients versus the ExAC database, we used Fisher
exact tests, since cell counts were often small. Because of
differences in data collection, a good threshold for signifi-
cance is hard to set. A conservative approach would be
alpha = (0.05/361) = 1.4e-4. In our analysis, P-values
were simply used to rank the genes.
As a threshold for significance for the other tests, we
used alpha = 0.01.
Results
One sample failed completely (median coverage < 1x).
Fourteen other samples had less than 70% of the target
covered at 20x, but they were still included in the analy-
sis. Median coverage of the included samples was 114x
(SD 57), complexity 45 (SD 14). Genes in our design
were on average covered at > 10x for 94.5% (SD 8) of
their length. MROH8 was covered for 35% and BHLHE22
not at all.
In the remaining cohort of 358 independent samples,
we identified in total 388 novel variants, i.e. not in
dbSNP 144, ESP server or ExAC database, varying from
0–8 per sample, single heterozygous variants in genes with
a presumed recessive effect on EE excluded. Of those vari-
ants 18 were frameshift indels, 5 were in-frame indels,
and the remainder were substitutions, which included 13
nonsense, one splice donor site and three splice acceptor
sites. Five variants occurred in two independent samples
each. Eighty-eight variants were found in genes annotated
as EE (55) or with related OMIM-annotations (33). An
overview can be found in supp. Table S1 and full list in
Table S2.
Patients of North-African or Middle Eastern descent
carried on average 1.6x as many novel variants per indi-
vidual as patients from European descent (Poisson,
P = 0.0002). A likely explanation is that the public data-
bases contain an excess of European samples, so polymor-
phisms specific to other geographical regions are
underrepresented.
Known EE genes and genes for related
phenotypes
Forty-one variants in 25 genes with an OMIM annotation
for EE, ID or related phenotype were followed up. By
investigating the segregation pattern and investigating the
phenotype, we found presumably pathogenic hits in
known genes in 29 patients: 20 in EE genes, and nine in
genes for related phenotypes (Table I in Table S1).
Heterozygous variants with a presumed dominant effect
were either novel or only seen in other patients, and they
were de novo. For the presumed recessive variants, they
were either earlier reported as pathogenic and very rare
(<1:10,000 in ExAC), or novel, and the treating clinician
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reported that the patient’s symptoms fit with gene, from
literature reports and their own experience. Exception is
presumed recessive rs376712059 in TBC1D24, which is
very rare and reported in ClinVar as “With Uncertain sig-
nificance allele”; the other variant in this gene is this
patient was reported as pathogenic before (Campeau et al.
2014). The clinician was convinced that this was a very
probable causal gene for this patient. In PNKP homozy-
gous LoF variants have been reported as pathogenic
before (Poulton et al. 2013), which is why we considered
this homozygous frame shift mutation as pathogenic. In
all patients listed in Table 1, the clinicians reported that
the gene was a likely fit for the patients’ symptoms.
Though prediction scores were not used to assess
pathogenicity, all variants in this Table have CADD
phred- scores >23.0.
In sporadic patients with presumably unrelated parents,
our follow-up experiments detected fifteen de novo vari-
ants in autosomal dominant-acting genes; four de novo
variants in X-linked genes, and three compound heterozy-
gous variant combinations in recessive-acting genes. One
of those compound heterozygous combinations was also
detected in an affected sib. In patients with related par-
ents, we detected three homozygous variants in recessive
genes, one homozygous variant in presumed dominant
gene GRIN1 (MIM 138249) and one compound heterozy-
gous variant combination in a recessive gene. Though
patients with related parents are presumed to be predis-
posed for recessive-acting variants, other inheritance
mechanism cannot be excluded. One patient with related
parents had a de novo variant. Heterozygous loss of func-
tion variants in X-linked gene WDR45 have been reported
as enriched in girls with EE-like phenotypes (Saitsu et al.
2013). We found an interesting in-frame indel in WDR45
(MIM 300526) hemizygous in a boy, though its signifi-
cance remains to be investigated. A complete list of all
novel variants and possibly pathogenic variants in reces-
sive genes can be found in Table S2.
We like to highlight a few interesting genes: We found
four patients with novel missense variants in SCN1A
(MIM182389) (Claes et al. 2001), and one with a frame-
shift variant. Of those, three were de novo, while two were
inherited, so probably not pathogenic. In addition, one
patient had a highly conserved splice region variant,
which had been seen in a Dravet patient before as a de
novo variant (Harkin et al. 2007).
Of special interest were the X-linked and recessive
genes. We found a de novo heterozygous nonsense muta-
tion in X-linked gene WDR45 (Haack et al. 2012; Saitsu
et al. 2013; Ohba et al. 2014; Ozawa et al. 2014) in a girl,
but also, as mentioned above, an in-frame indel in a boy.
This gene is described as influencing EE-phenotypes in an
X-linked dominant fashion. The inheritance in the boy
will be investigated, but we currently consider it as a vari-
ant of unknown significance.(Haack et al. 2012). In
IQSEC2 (MIM 300522) (Shoubridge et al. 2010; Epi4K-
Consortium et al. 2013; Gandomi et al. 2014; Tran
Mau-Them et al. 2014), we found a hemizygous de novo
variant in a boy, and a heterozygous de novo variant in a
girl (Morleo et al. 2008; Olson et al. 2015). Though
IQSEC2is described in OMIM as acting in a dominant
fashion, we considered both variants as pathogenic
(Kalscheuer et al. 2015).
Prioritizing and variant characteristics
We hypothesized that ranking the frequency of unique
hits per gene relative to the ExAC database was the most
relevant variable for prioritizing candidate genes, despite
some caveats (see Discussion). None of the genes showed
significant excess in EE cases (Fisher exact, Bonferroni
correction). Among the genes with excess novel variants
(OR > 1.0) were relatively more known EE and epilepsy-
related genes than among genes with fewer novel variants
(P < 0.0001; see Table S3), and in the top ten, six genes
were EE or epilepsy-related. We selected a shortlist of
candidate genes for follow-up. Part of those genes were
selected because they were top-ranking in the list with
excess unique variants, while a few others were added
because of preliminary data of independent studies of
some of the investigators. Our follow-up list can be found
in Table S1.
We divided the genes with excess novel variants
(OR > 1) in (1) known EE genes, (2) genes in OMIM
with intellectual disability or with an epilepsy-related
phenotype, (3) candidate genes without known related-
ness to epilepsy. For these three sets, we compared
CADD-scores for unique variants in our patients with
CADD-scores of unique variants in the ExAC database.
We found an interaction effect (P = 0.002), where in the
EE genes, the CADD-scores in our patients were higher
than in the ExAC database, while this difference was not
visible in the candidate genes (Fig. 1).
In the known EE genes, we compared CADD-scores for
variants that were eventually considered pathogenic, based
on inheritance and phenotype, with variants that were
considered benign, such as inherited variants in dominant
genes. The presumed pathogenic variants, both in domi-
nant and recessive-acting genes had on average higher
CADD-scores than the presumed benign variants (P = 5.7
106, Fig 2), supporting their involvement in disease.
Because both excess unique variants and high CADD-
scores seem to be correlated with gene pathogenicity, we
plotted both, to identify promising genes (Fig. 3).
In addition to excess and CADD-scores, we looked at
loss-of-function (LoF) variants. In our dataset, we found
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34 possibly suspect LoF variants, of which 31 novel and
three rare in a recessive gene (Table 2). Eighteen of those
were in genes that are intolerant to loss of function vari-
ants according to Samocha et al.’s pLi-score (pLi> 0.95)
(Samocha et al. 2014). LoF variants in our dataset
occurred more often in intolerant genes than expected by
chance (P < 105). When restricted to the candidate
genes only, the excess was less pronounced, but still sug-
gestively significant (one-sided P = 0.025). Most of those
genes, though, also had some LoF-variants in the ExAC-
database (Table 2), and careful inspection of the position
and consequence of all LoF variants in the gene is needed
Table 1. Probably pathogenic variants confirmed in follow-up.
ID Sex Genotype Gene Variant (aa)1
Expected
gene
inheritance Family tested OMIM morbid description2
2012D09029 M Hemi CASK p.R584X X-linked De novo Mental retardation and microcephaly
with pontine and cerebellar hypoplasia
2008D06721 F Hetero EEF1A2 p.G70S Dominant De novo Epileptic encephalopathy, early infantile, 33
EG1761 F Hetero FARS2 p.T156M Recessive Compound het Combined oxidative phosphorylation
deficiency 14
EG1761 F Hetero FARS2 c.905-1G>A
(splice-acceptor)
Recessive Compound het Combined oxidative phosphorylation
deficiency 14
EP2201 F Hetero GNAO1 p.G40R Dominant De novo Epileptic encephalopathy, early infantile, 17
EP2822 M Hetero GPHN p.D422N Recessive Compound het Molybdenum cofactor deficiency,
complementation group c
EP2822 M Hetero GPHN c.1315-2A>G
(splice-acceptor)
Recessive Compound het Molybdenum cofactor deficiency,
complementation group c
EP1718 M Homo GRIN1 p.Q556X Dominant Inherited from
het parents
Mental retardation, autosomal dominant 8
EP2797 M Hetero GRIN1 p.G827R Dominant De novo Mental retardation, autosomal dominant 8
2012D06376 Hetero HNRNPU pV604 fs Dominant De novo Candidate
2010D12136 M Hemi IQSEC2 p.Y1129X X-linked De novo Mental retardation, x-linked 1
EP1961 F Hetero IQSEC2 p.G771D X-linked De novo Mental retardation, x-linked 1
2010D05815 F Hetero KCNB1 p.F416L Dominant De novo Epileptic encephalopathy, early infantile, 26
KIEL20 M Hetero KCNB1 p.R312H Dominant De novo Epileptic encephalopathy, early infantile, 26
2012D20026 M Hetero KCNQ2 p.Y363H Dominant De novo Epileptic encephalopathy, early infantile, 7
KIEL42 F Hetero KCNQ2 p.R532W Dominant De novo Epileptic encephalopathy, early infantile, 7
2009D12616 F Hetero KCNT1 p.R429C Dominant Not tested Epileptic encephalopathy, early infantile, 14
EP2788 F Hetero KCNT1 p.R429H Dominant De novo Epileptic encephalopathy, early infantile, 14
EP95 M Hetero KCNT1 p.R429C Dominant De novo Epileptic encephalopathy, early infantile, 14
1011L F Homo PNKP p.A420 fs Recessive Inherited from
het parents
Epileptic encephalopathy, early infantile, 10
395M F Homo POLG p.R1096C Recessive Inherited from
het parents
Leigh syndrome
EP1781 F Hetero SCN1A p.C968G Dominant De novo Epileptic encephalopathy, early infantile, 6
EUR577 F Hetero SCN1A p.I1347T Dominant De novo Epileptic encephalopathy, early infantile, 6
KIEL38 M Hetero SCN1A p.D702 fs Dominant De novo Epileptic encephalopathy, early infantile, 6
EP1789 F Hetero SCN2A p.L1665F Dominant De novo Epileptic encephalopathy, early infantile, 11
EP2104 M Hetero SCN2A p.Q1811E Dominant De novo Epileptic encephalopathy, early infantile, 11
2010D14438 F Hetero SLC13A5 p.S427L Recessive Compound het Epileptic encephalopathy, early infantile, 25
2010D14438 F Hetero SLC13A5 p.G219R Recessive Compound het Epileptic encephalopathy, early infantile, 25
EP2821 F Homo SLC25A22 p.Q117R Recessive Inherited from
het parents
Epileptic encephalopathy, early infantile, 3
EP2806 F Hetero SPTAN1 p.R2037W Dominant De novo Epileptic encephalopathy, early infantile, 5
EP2514 M Hetero STXBP1 p.P480L Dominant De novo Epileptic encephalopathy, early infantile, 4
2013D03222 M Double het TBC1D24 p.E153K Recessive Testing Epileptic encephalopathy, early infantile, 16
2013D03222 M Double het TBC1D24 p.H336 fs Recessive Testing Epileptic encephalopathy, early infantile, 16
2008D07479 F Hetero WDR45 p.E155X X-linked
dominant
De novo Neurodegeneration with brain iron
accumulation 5; SENDA
Compound heterozygotes are shaded in gray.
1Complete notation with accession numbers can be found in the supplementary table.
2Morbid description in OMIM. Only the most relevant phenotype is listed here.
573ª 2016 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
C. G. F. de Kovel et al. Targeted Sequencing in Epileptic Encephalopathy
to assess the possible impact of the variants found in our
experiment. Clearly not all of those variants should be
considered the main cause for the patient’s symptoms.
Follow-up of variants in candidate genes
We followed up 31 patients in the prioritized candidate
genes. In the recessive candidate genes, double heterozy-
gote or homozygote genotypes were rare (Table S1). All
variants in candidate genes turned out to be inherited,
except one: in the gene HNRNPU (MIM 602869) we
identified a de novo mutation (Table I in Table S2). Like
other recently published pathogenic variants in HNRNPU
(Need et al. 2012; Carvill et al. 2013; Epi4K-Consortium
et al. 2013; Hamdan et al. 2014), (https://decipher.
sanger.ac.uk/ddd#research-variants/snvs, http://www.ncbi.
nlm.nih.gov/clinvar/?term=hnrnpu[gene]), this variant
causes termination of the transcript. Nonsense mediated
decay is a possible consequence. The gene is located
within the region 1q43q44 where a recurrent microdele-
tion is found, which has been detected in patients with
intellectual disability, microcephaly, craniofacial anoma-
lies, seizures, limb anomalies, and corpus callosum abnor-
malities (Caliebe et al. 2010; Thierry et al. 2012). The
gene is expressed in fetal and adult human brain, in par-
ticular in the adult cerebellum (Thierry et al. 2012), and
is found as part of the spliceosome C (Chen et al. 2007).
The phenotype of the patient is described in supplement
S4.
Discussion
In this study, we performed a follow-up screen of candidate
genes for EE in a new set of patients. After we had designed
the project, EIEE26 and higher EEIE-numbers were added
to OMIM-annotated genes for EIEE. Our experiment
therefore lacks the EIEE-genes WWOX (MIM 605131;
EIEE28), AARS (MIM 601065; EIEE29), SIK1 (MIM
605705; EIEE30) and KCNA2 (MIM 176262; EIEE32).
Among theEIEE genes in our design, likely pathogenic vari-
ants were found in recently discovered genes GRIN2B
(MIM 138252;EIEE27), EEF1A2 (MIM 602959; EIEE33)
and KCNB1 (MIM 600397; EIEE26). Our findings will help
to expand on the phenotype descriptions associated with
these genes, in separate publications.
In three unrelated patients, different novel variants in
the gene GPHN were found, including one as a homozy-
gote. This gene is described as showing recessive inheri-
tance for various disorders, among which encephalopathy
due to sulphite oxidase deficiency and Molybdenum
Cofactor Deficiency (Reiss et al. 2001; Lionel et al. 2013).
When comparing this number of novels in our data to
the number of rare variants in ExAc as described, there
was a relatively large excess in our data. Also, the gene is
thought to be intolerant to LoF and missense variation
(Samocha et al. 2014; Ware et al. 2015). Despite these
observations, it seems unlikely that, these unique variants
can by themselves explaining the disorder of the patient.
Despite searching our data, we found no second possibly
pathogenic variant in the heterozygote patients. Further-
more, the patient with a homozygote genotype had,
according to the treating clinician, a phenotype that was
not compatible with GPHN mutations.
Figure 1. Raw CADD-scores for novel unique variants in our patient
cohort versus unique variants in the ExAC database in three gene
categories. (In all figures: note that most indels get no CADD-scores).
Figure 2. Raw CADD-scores for novel variants in our patient cohort
in known genes for EE or related phenotypes. After checking the
variants in relatives, and considering the patient’s phenotype, variants
were classified into probably benign and probably pathogenic.
Recessive- and dominant-acting genes are shown separately.
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Also surprising were a homozygote nonsense variant in
GRIN1 (Lemke et al. 2016) and a homozygote very rare
missense variant in GNAO1 (MIM 139311) rs758424351,
both of which are described as genes with a dominant
effect on EE. The phenotype of the patient with the
GNAO1 variant was not similar to phenotypes earlier
described for dominant GNAO1 mutations (Supp. S4)
(Nakamura et al. 2013).
Seven patients in whom we found the variants that
could probably explain their condition had related par-
ents. Four of those had homozygous variants that we con-
sidered pathogenic, and one was compound heterozygous
for a recessive gene. Of nineteen patients without related
parents for whom we found the variants probably
explaining their condition, none of the explaining variants
was homozygous, but three patients were compound
heterozygous for recessive genes. Though these observa-
tions are sparse for statistics, they are consistent with the
idea that patients with related parents are more likely
than patients with unrelated parents to suffer from a
recessive form of EE (one-sided P = 0.01).
In support of other literature, our findings in X-linked
genes IQSEC2 and WDR45 question whether their
description in OMIM as X-linked dominant for EE-like
phenotypes is the only possible mode of action. In
IQSEC2, variants were shown before to have an effect on
intelligence in males and females (Gandomi et al. 2014;
Tran Mau-Them et al. 2014; Kalscheuer et al. 2015). In
WDR45, loss-of-function variants are pathogenic in
females, but in males are assumed to be incompatible
with life (Haack et al. 2012). However, milder hemizy-
gous variants may turn out to be variants of large effect
on an ID or EE-like phenotype in males.
We prioritized a number of presumed dominant-acting
candidate genes for follow-up, and we Sanger-sequenced
patients’ relatives for those genes if DNA was available
(Table S1). Only an LoF variant in the candidate gene
HNRNPU was de novo, so only for this gene we found
supportive evidence for involvement in EE. Published
information about this gene, combined with our own
clinical data suggests a syndrome starting with early
developmental delay, and followed by fever-sensitive
epileptic seizures within the first year of life. Later, afeb-
rile seizures may develop. Developmental delay in
described cases was severe, and various additional
anomalies were mentioned (Need et al. 2012; Carvill
et al. 2013; Epi4K-Consortium et al. 2013; Hamdan et al.
2014) (https://decipher.sanger.ac.uk/ddd#research-variants/
snvs, http://www.ncbi.nlm.nih.gov/clinvar/?term=hnrnpu
[gene]). Phenotypic overlap may exist with patients with a
1q44 microdeletion encompassing this gene (Caliebe et al.
2010).
For all results, there is the caveat that we did not test
whether the parental samples were from the true parents.
For the patients with presumably recessive-acting variants,
all variants were shown to be inherited, but for de novo
variants we have no guarantees.
Prioritization
Our first tool to prioritize genes was calculating excess
frequency of unique variants in our patients versus the
population in the ExAC database. Because of differences
in technology, huge differences in sample size, and impre-
cise estimate of coverage in both datasets, the size of the
excess or P-value may not be accurate. Yet, the fact that
the ranking favored many known EE genes, even though
most samples had been through more or less extensive
diagnostic screening, shows that ranking based on excess
of unique variants is a valid tactic.
Figure 3. Per gene: Excess frequency of novel
variants in TEGA versus ExAC database (X-axis)
versus average CADD-scores for novel variants
in TEGA samples (Y-axis). Genes are classified
into known EE genes, genes for intellectual
disability, or phenotypes that may present with
seizures, and candidate genes.
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Table 2. Novel or very rare loss of function variants.
ID Variant (hg19) Genotype Gene Variant (aa)1,2,3
Expected
gene
inheritance
Gene pLI4
(Samocha)
No. LoF
per gene
in ExAC
EP949 chr12:123433309-T/- Hetero ABCB9 p.N305 fs*35 Dominant 0.00 7
KIEL99 chr17:48736728-C/T hetero ABCC3 p.R269X Dominant 0.00 30
EUR578 chr19:13563750-GGAAGGC/- Hetero CACNA1A p.A158 fs*6 Dominant 1.00 4
2012D09029 chrX:41414858-G/A Hemi CASK p.R584X X-linked 1.00 1
2007D04829 chr15:93527629-TCAT/- Hetero CHD2 p.I1046 fs*8 Dominant 1.00 5
2010D08930 chr15:93563370-C/T Hetero CHD2 p.R1679X Dominant 1.00 5
2008D06063 chr22:38694137-G/- Hetero CSNK1E p.257 fs (minor
transcripts)
Dominant 0.97 1
2012D20026 chrX:96603116-G/C Hemi DIAPH2 c.2847-1G>C
(minortranscripts,
missense in other
rs775057363)
X-linked 1.00 3
EUR585 chr3:132235289-TT/- Hetero DNAJC13 p.L1837 fs*48 Dominant 1.00 8
EG1761 chr6:5545412-G/A Hetero FARS2 c.905-1G>A
(splice-acceptor)
Recessive 0.00 10
D03/4526 chr11:134175014-A/- Hetero GLB1L3 p.A294 fs*2
(minor transcripts)
Dominant 0.00 22
D04/1316 chr11:134183917-GA/- Hetero GLB1L3 p.E555 fs*50 Dominant 0.00 22
2006D07509 chr16:56226254-T/G Hetero GNAO1 p.L36X Dominant 0.98 0
EP2822 chr14:67578576-A/G Hetero GPHN c.1315-2A>G
(splice-acceptor)
Recessive 1.00 1
KIEL38 chr19:6731282-G/T Hetero GPR108 p.Y454X Dominant 0.00 16
EP1718 chr9:140056657-C/T Homo GRIN1 p.Q556X Dominant 0.97 4
2012D06376 chr1:245019802–/A Hetero HNRNPU pV604 fs *24 Dominant 1.00 1
2010D12136 chrX:53265568-G/T Hemi IQSEC2 p.Y1129X X-linked 0.98 1
EP1852 chr20:47990498-G/T Hetero KCNB1 p.Y533X Dominant 0.98 1
2012D18530 chr15:52664419-T/A Hetero MYO5A p.K907X Dominant 0.99 16
EUR574 chr2:206617582-G/T Hetero NRP2 p.G643X Dominant 0.00 11
D04/2814 chr5:140603538-G/- Hetero PCDHB14 p.M154 fs*42 Dominant 0.00 12
2012D20026 chr3:126723726-A/G Hetero PLXNA1 c.1620-2A>G
(splice-acceptor)
Dominant 1.00 5
1011L chr19:50365068–/CGACC Homo PNKP p.A420 fs*49
(rs768847609)
Recessive 0.00 13
KIEL92 chr17:40278712-C/T Hetero RAB5C p.W130X (minor
transcripts)
Dominant 0.83 1
KIEL38 chr2:166898868-AAAGT/- Hetero SCN1A p.D702 fs*25 Dominant 1.00 2
2010D14485 chr20:1293995–/C Hetero SDCBP2 p.124-125-fs*33 Dominant 0.41 2
2006D07509 chr17:80218938–/A Hetero SLC16A3 p.296 fs (minor
transcript)
Dominant 0.33 2
KIEL92 chr5:168123348-G/- Hetero SLIT3 p.T1017 fs*24 Dominant 0.99 11
EP2103 chr4:99064223-G/A Hetero STPG2 p.Q27X Dominant 0.00 18
2013D03222 chr16:2548263-T/- Hetero TBC1D24 p.H336 fs*11 Recessive 0.00 10
D02/2287 chr6:30123503-C/T Hetero TRIM10 c.928 + 1G>A
(splice-donor)
Dominant 0.00 10
EP2805 chr4:39257574-T/G Hetero WDR19 p.Y1036X Dominant 0.00 20
2008D07479 chrX:48933578-C/A Hetero WDR45 p.E155X X-linked
dominant
0.97 0
Bold values indicate significant intolerance score.
1Frameshift consequences calculated with SIFT (Hu and Ng 2012). Nonsense-mediated decay predicted for all frameshifts except chr19:50365068
–/CGACC, chr11:134175014-A/- and chr22:38694137-G/-.
2Some variants occur only in less well supported transcripts (“minor transcripts”).
3Full description of variants including accession number in Tables S1–S3.
4Loss-of-function intolerance score according to Samocha et al. (2014). Score ranges 0–1, with high scores meaning less tolerant.
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Known EE genes not only showed on average an excess
of unique variants in our patients relatively to the ExAC
population, but also, on average, the unique variants in
these EE-genes in our patients were more deleterious, as
assessed by the CADD-scores, than those in the same
genes in the ExAC population. Higher CADD-scores were
also found in genes annotated as ID-genes or other
related phenotypes (in particular CDKL5 (MIM300203),
IQSEC2, FARS2 (MIM 611592), CASK (MIM 300172),
POLG (MIM174763)). Though some candidate genes also
showed an excess of unique variants relative to the ExAC
populations, these genes did not seem to have excessively
high CADD-scores on average in our patients for unique
variants. So if high average CADD-scores are an indica-
tion of gene pathogenicity, the high-ranking candidate
genes probably contained few true EE genes. It should be
noted that CADD-scores were only available for missense
variants, while for example in GLB1L3 two of the three
unique variants were indels. Therefore, the contribution
of loss-of-function variants due to frameshifts may be
underestimated.
In a recent paper (Grozeva et al. 2015), a large cohort
of patients with intellectual disability were sequenced
without the parents for a set of candidate genes, as was
done in this study. The authors also used enrichment of
rare variants versus a control group as a criterion for
pathogenicity of genes, though they had a stronger focus
on LoF variants. They estimated that ~8% of their cohort
had a pathogenic loss-of-function variant. While our
dataset seems enriched for possibly pathogenic LoF-var-
iants (Table I, Supporting Information), the estimate for
our EE patients will probably be lower.
Our cohort contained patients whose inclusion criteria
contained seizures. In less selected cohorts of patients
with developmental delay (e.g., Decipher Developmental
Delay cohort (McRae et al. 2016)), it was shown that a
considerable proportion of patients who have a presumed
pathogenic variant in an epilepsy-associated gene are
described as having no seizures. Similarly, presumed
pathogenic variants in intellectual disability or develop-
mental delay associated genes are found in patients with
seizures. The nonepilepsy genes in our design had been
selected because they were reported with suspect variants
in epilepsy patients before. Our analysis confirms that
patients with presumed pathogenic variants in these genes
(in Table S1 as “related” or “ID”) have been clinically
interpreted as patients with epileptic encephalopathy,
showing that there is considerable overlap. We found 13
presumed pathogenic DNMs in 29 genes with a dominant
inheritance mode for EE, and 5 presumed pathogenic
DNMs in 22 genes with a dominant inheritance mode for
related phenotypes. This is in addition to recessively
acting genotypes.
In the DDD paper, 23% of patients had a DNM in
a known gene, which could explain the presence of
the disorder. In our cohort, only ~6% of patients had
an explaining DNM in a known gene. However, our
sample was enriched for patients with presumably
inherited pathogenic variants. If only considering the
sporadic patients whose parents were not known to be
related (N = 251), the proportion that could be
explained by a DNM in a known gene was still only
~7%. Around 40 additional patients had variants in
known EE or ID genes, but could not be followed up
within the current project. Among those variants, a
proportion will likely be explanatory for the patient’s
disorder. For some of the patients, the variants (domi-
nant or recessive) that we identified in candidate
genes, but could not follow-up, will likely be the main
cause of their disorder. Following up on all other
identified variants, and screening the remaining
patients for a wider set of epilepsy or developmental
delay associated genes will likely increase the propor-
tion of patients with a genetic explanation.
The limited number of variants that could be followed
up, due to money constraints, unavailability of parental
DNA and consent issues, is a limitation of this study. We
selected the most promising candidate genes for follow-
up, and only found a single likely pathogenic variant. Yet,
some other candidate genes may still turn out to harbour
pathogenic mutations.
In conclusion, we found pathogenic variants in known
EE genes, including recently identified epilepsy genes, but
also in genes annotated for ID or other related pheno-
types. We could not convincing show that any of the
other candidate genes was a true EE gene. For HNRNPU
we provided supportive evidence. Excess of loss of func-
tion variants suggests that a few more candidate genes
may be real EE genes, but relatively low CADD-scores for
unique variants suggests that many of our candidate genes
are not relevant for EE.
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